Furthermore, clinical studies have revealed that bitter-tasting drugs increase endogenous GDF15 expression in obese patients via bitter taste receptors (TAS2Rs) in the intestinal epithelium, suggesting that TAS2Rs may represent novel therapeutic targets for combination therapy in obesity [61]. Here, GDF15 is linked to obesity due to melanocortin 4 receptor deficiency.